Harjinder Singh

Harjinder Singh, MD, FCCP, currently serves as the Director, Clinical Scientist at Atossa Therapeutics, Inc., where responsibilities include leading the Clinical Development Plan and overseeing ongoing trials for (Z)-endoxifen in breast cancer. Previously, Harjinder Singh held the position of Clinical Scientist at ProSciento, Inc., focusing on early clinical development for various metabolic conditions. Additional experience includes serving as Director of Clinical Research Operations at UT Health San Antonio and Director of Clinical Development at the Asthma and Allergy Research Center, where contributions involved developing strategies for clinical trials and novel assessment tools. Harjinder Singh's educational background includes an MD from Kuban State Medical University and certification in clinical trials from Parexel Academy.